Kairous Acquisition Corp. Limited - Rights Stock (NASDAQ: KACLR)

Latest news for Kairous Acquisition Corp. Limited - Rights (NASDAQ:KACLR) Stock

Kairous Acquisition Corp. Limited - Rights

Earnings

News

GROY

Gold Royalty Reports Reported Q2 Preliminary Revenue Of $1.79M

Leerink Partners analyst Andrew Berens initiates coverage on Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) with a Outperform rating and announces Price Target of $29.

Price Target

Initiation

Analyst Ratings

CELC

Leerink Partners Initiates Coverage On Celcuity with Outperform Rating, Announces Price Target of $29

HC Wainwright &amp; Co. analyst Andrew Fein reinstates Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) with a Buy and announces $80 price target.

CRBP

HC Wainwright & Co. Reinstates Buy on Corbus Pharmaceuticals, Announces $80 Price Target

&nbsp;<a href="https://www.nuvalent.com/" target="_blank">Nuvalent, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVL#NASDAQ">NUVL</a>), a clinical-stage biopharmaceutical company focused on creating&nbsp;precisely&nbsp;targeted therapies for clinically proven kinase targets in cancer, today announced the initiation of HEROEX-1, its Phase 1a/1b&nbsp;clinical trial evaluating its novel HER2-selective inhibitor, NVL-330, for pre-treated patients with HER2-altered non-small cell lung cancer (NSCLC).

NUVL

Nuvalent Begins Phase 1 Trial for New HER2-Selective Lung Cancer Treatment

Although expected, when President Joe Biden announced Sunday<a href="https://www.benzinga.com/general/politics/24/07/39874057/biden-drops-out-of-2024-race-in-bombshell-announcement-it-has-been-the-greatest-honor-of-my-life"> his intention to quit the 2024 race,</a> it created ripples. A snap poll conducted shortly after the president&#8217;s announcement showed a majority of Americans approved of the decision. 
Biden&#8217;s Decision: 71% percent of the Americans surveyed said they either strongly approved or somewhat approved of Biden&#8217;s withdrawal, YouGov&#8217;s survey <a href="https://today.yougov.com/topics/politics/survey-results/daily/2024/07/21/ef555/1">showed.</a> The survey was conducted on Sunday after Biden&#8217;s announcement and 2,048 adults were surveyed for the purpose. A total of 16% said they either disapproved or somewhat disapproved, and 12% said they weren&#8217;t sure.
Party-wise breakup of the responses showed that the percentage of Americans who approved of (strongly/somewhat) the decision was:
<ul>
<li>70% Democrats</li>
<li>68% Independents</li>
<li>77% Republicans</li>
</ul>
See Also: <a href="https://www.benzinga.com/news/24/07/39873597/anthony-scaramucci-says-if-democrats-win-they-can-extinguish-large-elements-of-trumpism-but-youre-no">Anthony Scaramucci Says If Democrats Win, They Can &#8216;Extinguish Large Elements Of Trumpism&#8217; But &#8216;You&#8217;re Not Going To Be Able To Do It If You Don&#8217;t&#8230;&#8217;</a>
Biden&#8217;s Replacement:<a href="https://www.benzinga.com/news/24/07/39874401/betting-markets-favor-kamala-harris-as-top-democratic-presidential-contender"> Vice President Kamala Harris </a>was picked as Biden&#8217;s replacement by 37% of the respondents, 35% wanted someone else and 27% said they weren&#8217;t sure. She snagged the support of a majority of her own party members, with 60% siding with her. Those rooting for someone else or who weren&#8217;t sure accounted for 21% and 19% of Americans who identified themselves as Democrats.
Among independents, Harris garnered the support of 30% of the respondents, while 36% sought someone else. A more modest 24% of Republicans picked Harris as a potential Biden replacement but 50% wanted someone else.
Trump&#8217;s Chances: Trump&#8217;s chances are bolstered by Biden&#8217;s decision to quit. 36% of Americans said Biden&#8217;s decision to step aside as the Democratic nominee makes Trump more likely to win, while 23% said it makes Trump less likely to win. 18% said the decision would have no impact and 23% weren&#8217;t sure.
More Democrats (37%) see the development as more negative for Trump, while only 23% and 8%, respectively of the independents and Republicans think likewise. The proportion of the Democrats, independents and Republicans who see Biden&#8217;s decision as positive for Trump is 22%, 34%, and 53%, respectively.
Trump Vs. Harris: In a hypothetical matchup, 34% of registered voters said they think Harris would win in an election against Trump, while 49% think Trump would win. Despite the big lead for Trump, Harris&#8217; performance was better than the Biden vs Trump tally, according to a July 13-16 Economist/YouGov poll. Biden received only 29% support in the mid-July poll compared to 50% support Trump got. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/money/how-to-invest-in-startups">How To Invest In Startups</a></li>
</ul>
Image via Shutterstock

Politics

Media

Trump Vs. Harris: First Poll After Biden's Exit Shows Majority Approve Of Decision, But Here's How It Might Affect Ex-President's Chances

Leerink Partners analyst Mani Foroohar initiates coverage on Benitec Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTC#NASDAQ">BNTC</a>) with a Outperform rating and announces Price Target of $13.

BNTC

Leerink Partners Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $13

HC Wainwright &amp; Co. analyst Robert Burns initiates coverage on Cargo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) with a Buy rating and announces Price Target of $33.

CRGX

HC Wainwright & Co. Initiates Coverage On Cargo Therapeutics with Buy Rating, Announces Price Target of $33

Earnings Beats

ISTR

Investar Holding Q2 2024 Adj EPS $0.36 Beats $0.29 Estimate, Sales $19.948M Beat $19.800M Estimate

Jefferies analyst Tycho Peterson upgrades 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) from Hold to Buy and maintains the price target from $24 to $24.

Upgrades

Jefferies Upgrades 10x Genomics to Buy, Maintains Price Target to $24

HC Wainwright &amp; Co. analyst Arthur He reiterates Adagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAG#NASDAQ">ADAG</a>) with a Buy and maintains $5 price target.

Reiteration

ADAG

HC Wainwright & Co. Reiterates Buy on Adagene, Maintains $5 Price Target

The Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) disclosed that it forecasts a 3% increase in airplane deliveries over the next 20 years, estimating a need for nearly 44,000 <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/n39869384/boeing-forecasts-demand-for-nearly-44-000-new-airplanes-through-2043-as-air-travel-surpasses-pre-p" rel="noreferrer noopener">new commercial airplanes by 2043</a>.
The global commercial fleet is expected to grow at an annual rate of 3.2%, slower than air traffic growth, as airlines enhance productivity by raising load factors and utilizing <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">airplanes for more hours each day</a>.
Boeing expects that emerging markets and global single-aisle market demand will be the main growth drivers for the industry.
By geographies, Boeing projects South Asia&#8217;s passenger traffic to grow by 7.4%, followed by Southeast Asia at 7.2% and Africa at 6.4%. Also, Eurasia will lead airplane deliveries with 22%, while North America and China will each account for 20%.
By 2043, single-aisle airplanes will comprise 71% of the fleet with 33,380 new deliveries, mainly for short- to medium-haul routes.
Read: <a target="_blank" href="https://www.benzinga.com/news/24/07/39818420/boeings-737-max-crisis-ripple-effects-disrupt-airlines-suppliers" rel="noreferrer noopener">Boeing&#8217;s 737 MAX Crisis Ripple Effects Disrupt Airlines, Suppliers</a>
The 2024 Commercial Market&nbsp;Outlook (CMO) forecasts that passenger air traffic will increase by an average of 4.7% annually over the next two decades compared to 2023.
Dan Abraham, senior vice president of Boeing Global Services Commercial Sales and Marketing, commented, &#8220;As airlines respond to robust passenger demand, the services market continues to expand, not only as a result of fleet growth, but also with an increased focus on reducing operating costs and deploying efficient and sustainable solutions.&#8221;&nbsp;
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/39788122/judge-allots-time-for-boeing-737-max-crash-victims-relatives-to-object-plea-deal-report" rel="noreferrer noopener">Judge Allots Time For Boeing 737 MAX Crash Victims&#8217; Relatives To Object Plea Deal: Report</a>
Boeing forecasts a $4.4 trillion demand for commercial services, fueled by maintenance, modifications, and digital solutions that enhance efficiency.
Today, Woodward, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WWD#NASDAQ">WWD</a>) has been chosen to supply rotary actuation solutions for NASA and Boeing&#8217;s Transonic Truss-braced Wing (TTBW) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g39876628/boeing-selects-woodward-to-design-innovative-rotary-actuator-for-the-nasa-sustainable-flight-demon" rel="noreferrer noopener">X-66A aircraft demonstrator</a>.
Last week, Boeing faced yet another challenge as Washington state factory workers voted overwhelmingly in favor of a strike mandate, amid the workers&#8217; demand for a 40% raise during their first <a target="_blank" href="https://www.benzinga.com/news/24/07/39836988/boeing-workers-vote-for-strike-mandate" rel="noreferrer noopener">full&nbsp;negotiation with Boeing&nbsp;in 16 years</a>.
Boeing stock has lost more than 16% in the last 12 months.&nbsp;Investors can gain exposure to the stock via&nbsp;IShares U.S.&nbsp;Aerospace &amp; Defense ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITA#BATS">ITA</a>) and&nbsp;Invesco Aerospace&nbsp;&amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPA#NYSE">PPA</a>).
Price Action: BA shares are up 0.46% at $180.50 premarket at the last check Monday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo Courtesy: Tada Images On Shutterstock.com
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39810693/boeing-delivers-critical-core-stage-for-nasas-lunar-mission-details" target="_blank" rel="noreferrer noopener">Boeing Delivers Critical Core Stage for NASA&#8217;s Lunar Mission: Details</a></li>
</ul>

Equities

Large Cap

Guidance

iShares Dow Jones US Aerospace & Defense Index Fund

Boeing's Commercial Market Outlook Predicts Soaring Demand: 44,000 New Airplanes Needed By 2043

On July 19, 2024, Allarity Therapeutics, Inc. (the &ldquo;Company&rdquo;) received a &ldquo;Wells Notice&rdquo; from the Staff of the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) relating to the Company&rsquo;s previously disclosed SEC investigation. The Wells Notice relates to the Company&rsquo;s disclosures regarding meetings with the United States Food and Drug Administration (the &ldquo;FDA&rdquo;) regarding the Company&rsquo;s NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021. The Company understands that all conduct relating to the SEC Wells Notice occurred during or prior to fiscal year 2022. Allarity also understands that three of its former officers received Wells Notices from the SEC relating to the same conduct. A Wells Notice is neither a formal charge of wrongdoing nor a final determination that the recipient has violated any law. The Wells Notice informed the Company that the SEC Staff has made a preliminary determination to recommend that the SEC file an enforcement action against the Company that would allege certain violations of the federal securities laws. The Company is continuing to cooperate with the SEC and maintains that its actions were appropriate, and intends to pursue the Wells Notice process, including submitting a formal response to the SEC.

Government

Regulations

ALLR

SEC Issues Wells Notice to Allarity Therapeutics and Former Officers Over 2021 FDA NDA Submission

Morgan Stanley analyst Ravi Shanker maintains Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) with a Overweight and lowers the price target from $75 to $70.

Morgan Stanley Maintains Overweight on Alaska Air Gr, Lowers Price Target to $70

Telsey Advisory Group analyst Sarang Vora maintains Coursera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) with a Outperform and maintains $18 price target.

COUR

Telsey Advisory Group Maintains Outperform on Coursera, Maintains $18 Price Target

Morgan Stanley analyst Kristine Liwag maintains Hexcel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) with a Underweight and lowers the price target from $63 to $61.

Morgan Stanley Maintains Underweight on Hexcel, Lowers Price Target to $61

Needham analyst Mayank Tandon reiterates Euronet Worldwide (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EEFT#NASDAQ">EEFT</a>) with a Buy and maintains $125 price target.

EEFT

Needham Reiterates Buy on Euronet Worldwide, Maintains $125 Price Target

Evercore ISI Group analyst Mark Mahaney initiates coverage on Webtoon Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) with a Outperform rating and announces Price Target of $30.

WBTN

Evercore ISI Group Initiates Coverage On Webtoon Entertainment with Outperform Rating, Announces Price Target of $30

The deal includes 20 777-9s and 20 787-10s with options for 10 more of the largest 787 Dreamliner variant.
When finalized and posted to Boeing&#39;s Orders &amp; Deliveries website, Korean Air will be the latest customer to purchase the world&#39;s largest and most fuel-efficient twin engine jet.

Contracts

Boeing Reveals Korean Air's Intent To Purchase Up To 50 Widebody Airplanes; No Terms Disclosed

China has made a surprising move to stimulate its economy by lowering key interest rates. The decision comes as the country faces several economic challenges, including weak growth <a target="_blank" href="https://www.benzinga.com/news/24/07/39768528/alibaba-chinese-tech-stocks-and-ev-stocks-nio-xpeng-li-auto-tumble-after-disappointing-economic-repo" rel="noreferrer noopener">in the second quarter</a>, looming deflation, and a prolonged property crisis.
Chinese stocks, including Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), PDD Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>), JD.Com, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), Baidu, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), Bilibili Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) are trading higher Monday.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/24/07/39810709/whats-going-on-with-alibaba-and-peer-chinese-stocks-on-wednesday" rel="noreferrer noopener">Alibaba and Peers Face Challenges as U.S. Tightens Semiconductor Export Rules</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22042007/newplot-50.png" alt="" class="wp-image-448053" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22042007/newplot-50.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/22042007/newplot-50-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
On Monday, the People&#8217;s Bank of China (PBOC) announced that it would cut the seven-day reverse repo rate to 1.7% from 1.8% and reduce the one-year loan prime rate (LPR) to 3.35% from 3.45%.
Additionally, China lowered the five-year LPR to 3.85% from 3.95%. These measures aim to boost economic activity and achieve the growth targets set during the recent plenum, Reuters reports.
The PBOC has also adjusted its lending programs. Starting in July, it will lower the collateral requirements for its medium-term lending facility loans.
Now, banks will need to hold fewer long-term bonds, enabling them to trade more freely and supporting the central bank&#8217;s efforts to stabilize long-term yields and prevent a bond bubble.
Following the rate cuts, Chinese sovereign bond yields fell, with 10-year and 30-year yields dropping by up to 3 basis points before stabilizing. China&#8217;s 30-year treasury futures for September 2024 delivery rose by approximately 0.3% in early trade on Monday.
<a target="_blank" href="https://www.benzinga.com/news/24/07/39877062/nvidia-reportedly-developing-a-new-version-of-its-flagship-ai-chip-for-chinese-market-amid-us-export" rel="noreferrer noopener">Separate reports indicated</a> that Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is developing a new AI chip tailored to meet U.S. export restrictions for China, which will boost stocks like Alibaba and Baidu, which are keen on pursuing their AI ambitions.
Alibaba stock lost 22% in the last 12 months as it battles macro and micro headwinds including cancellation of IPOs of its logistics and cloud business and intense domestic e-commerce rivalry from PDD. Baidu lost over 39% as its AI models strive to gain traction. JD.Com&nbsp;lost 32% and Bilibili in the last 12 months. PDD gained 69%.
Price Action:&nbsp;BABA shares are trading higher by 1.66% to $76.52 in the premarket session at the last check on Monday.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/24/07/39857256/whats-going-on-with-alibaba-stock-on-friday" rel="noreferrer noopener">Alibaba Faces Setbacks with AI Expert Departure Amidst Regulatory Pressures</a>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by Eric Prouzet on Unsplash

Emerging Markets

BABA

BIDU

BILI

NVDA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

What's Going On With Alibaba And Other Chinese Stocks On Monday?

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) with a Neutral.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

Kairous Acquisition Corp. Limited - Rights

News

Latest news for Kairous Acquisition Corp. Limited - Rights (NASDAQ:KACLR) Stock